Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASH 2015
ASH 2015 – Castleman's Disease, Lymphoma, and CLL
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
Obinutuzumab plus Ibrutinib as Induction and Maintenance Therapy After Bendamustine Debulking in Patients with CLL: Interim Results of a Phase 2 CLL2-BIG Trial
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib versus Chlorambucil in Patients >65 Years with Treatment-Naïve CLL/SLL: Results from the Phase 3 RESONATE-2 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Phase 2 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib versus Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle-Cell Lymphoma (MCL)
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Syk Inhibitor Entospletinib Monotherapy in CLL/SLL: Phase 2 Trial Results
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Idelalisib plus Bendamustine/Rituximab versus Bendamustine/Rituximab in Relapsed/Refractory CLL: Results of a Phase 3 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma